Intraday Info: Corium International Inc (NASDAQ:CORI) locked on 12/12/2016 at $4.89. It has average volume $36.35K whilst it total volume $3,903. The company has EPS -1.65 and according to analysts next quarter EPS and next year estimate EPS will -0.42 and -1.54 respectively. And it total income -36.70 million.
Ownership Summary: Corium International Inc has total institutional ownership 88.24% while its total outstanding shares 22 millions that’s value of holdings $99 million.
Active Positions: In the latest year, CORI 11 holders have raised its positions while it contains total 477,122 shares. And the strength of reduced positions holders and held positions holders are 18 and 12 respectively.
New and Sold Out Positions: In CORI force of new positions holders 2 and it has total shares 74,897. And force of sold out positions holders 7 and it has 104,771 shares.
Comparison with Other Company: The Market Value of CORI is $109,336 below from Alexion Pharmaceuticals, Inc. market value which is $25M. Current Last Sale of CORI is $4.89 below from ALXN current last sale which is $115.08.
Corium international, Inc. declared unaudited economic results for the fourth financial region and the yr ended September 30, 2016, and said on latest company tendencies. Corium’s financial year ends on September 30.
Corium said total revenues inside the fourth zone of fiscal 2016 of $7.9 million, assessment with $nine.three million within the fourth quarter of fiscal 2015, and for the financial year ended September 30, 2016, said general revenues of $33.0 million, assessment with $forty.9 million in fiscal 2015. For fiscal 2016, the lower in total revenues resulted in particular from a decline in agreement research and development sales, further to a decline in product revenues as evaluation to fiscal 2015. The lower in agreement research and improvement sales is especially the end result of numerous programs advancing into later stages of medical improvement, whilst there are fewer revenue-producing development sports until arrangements start for approval and commercial release, together with the discontinuation of two improvement projects in fiscal 2015. The $1.2 million decline in product sales for fiscal 2016 evaluation to monetary 2015 is particularly the end result of fewer Fentanyl TDS devices ordered and shipped, which changed into partly offset via a lift in sales from Crest® Whitestrips.
General studies and improvement (R&D) expenses in the fourth area of financial 2016 have been $eight.2 million, evaluation with $eight.6 million in the fourth sector of fiscal 2015, and for the monetary year ended September 30, 2016, total R&D expenses were $32.4 million, evaluation with $32.5 million in economic 2015. For economic 2016, R&D costs related to Corium’s funding in its proprietary product programs raised, counting the development of Corium’s programs for Alzheimer’s ailment via section 1 scientific trials. This boom in R&D spending turned into offset by using a decrease stage of resources required for settlement research and improvement packages, similar to the lower level of revenues from settlement research and development.